0 CHECKOUT

Japan Proton Therapy Outlook 2020

  • ID: 3494102
  • November 2015
  • Region: Japan
  • 55 pages
  • RNCOS E-Services Private Limited
1 of 4

In the field of cancer treatment, Japan was second among the world’s countries to offer proton therapy. However, the access to proton therapy is limited for a vast population, owing to a low number of proton therapy centers. Hence, a large number of research institutions and hospitals have started investing in proton therapy to make it more accessible to the colossal pool of cancer patients.

According to the “Japan Proton Therapy Outlook 2020” report by 2020, there will be 13 operational proton therapy centers in Japan. Consequently, the market will attain revenue of around US$ 150 Million by 2020, growing at a CAGR of 13% during the forecast period of 2015-2020. The report also provides an insight into the cancer demographics of Japan and the various possible reasons for an increasing incidence of cancer patients in the country.

Based on a complex correlation-regression model accounting population demographics, disease statistics, macro & micro economic indicators of the country, and more, the report provides an account of the potential proton therapy market in Japan. The report also includes the current and future demands for the number of proton READ MORE >

Note: Product cover images may vary from those shown
2 of 4

1. Analyst View

2. Research Methodology

3. Japan Cancer Demographics
3.1 Incidence by Site

4. Current Radiation Therapies
4.1 Third Dimensional Conformal Therapy (CRT)
4.2 Image Guided Radiotherapy (IGRT)
4.3 Intensity Modulated Radiotherapy (IMRT)
4.4 Stereotactic Radiotherapy
4.5 Neutron Therapy
4.6 Heavy Ion Radiotherapy
4.7 Proton Therapy
4.7.1 Need for Proton Therapy

5. Components of a Standard Proton Therapy Center
5.1 Proton Accelerator
5.2 Beam Transport System
5.3 Beam Delivery System
5.4 Nozzle
5.4.1 Single Scattering
5.4.2 Double Scattering
5.4.3 Uniform Scanning Nozzle
5.4.4 Pencil Scanning Nozzle
5.5 Treatment Planning System
5.6 Image Viewers
5.7 Patient Positioning System
5.8 Human Resource

6. Japan Proton Therapy Market
6.1 Current Market Size and Future Growth
6.2 Potential Patients
6.2.1 Market Penetration
6.3 Opportunity Assessment
6.4 Existing and Forthcoming Players Analysis
6.4.1 Equipment Providers
6.5 Proton Therapy Centers Analysis

7. Market Dynamics
7.1 Drivers
7.1.1 Increasing Incidence of Cancer
7.1.2 Benefits of Proton Therapy over Conventional Therapies
7.1.3 Low Cost of Treatment
7.1.4 High Disposable Income
7.2 Challenges
7.2.1 Increasing Adoption of Carbon Ion Radiotherapy
7.2.2 Reimbursement Issues
7.3 Opportunity
7.3.1 Medical Tourism

8. Market Trends
8.1 Centers with Lesser Number of Treatment Rooms
8.2 Dominance of Domestic Players in Proton Therapy Market

9. Competitive Landscape and Strategic Analysis
9.1 Hitachi Medical Corporation (A Subsidiary of Hitachi Ltd.)
9.2 Sumitomo Heavy Industries, Ltd.
9.3 Mitsubishi Electric Corporation

List of Tables
Table 3-1: Cancer Incidence Growth by Site (2015-2035)
Table 5-1: Human Resource Requirements and their Role in Proton Therapy Center
Table 6-1: Potential Patients for Proton Therapy (2015 & 2020)
Table 6-2: Proton Therapy Centers, (2015)
Table 6-3: Upcoming Proton Therapy Centers (2015 - 2020)
Table 6-4: Proton Therapy Equipment Providers with Number of Installations, (2015)
Table 6-5: Proton Therapy Equipment Providers with Number of Installations by 2020
Table 9-1: Hitachi - Key Financials (Millions US$), 2013-2015
Table 9-2: Hitachi - Proton Therapy Installations in Japan
Table 9-3: Hitachi - Upcoming Proton Therapy Installations in Japan
Table 9-4: Hitachi - Strengths and Weaknesses
Table 9-5: Sumitomo - Key Financials (Million US$), 2013-2015
Table 9-6: Sumitomo - Proton Therapy Installations in Japan
Table 9-7: Sumitomo - Upcoming Proton Therapy Installations in Japan
Table 9-8: Sumitomo - Strengths and Weaknesses
Table 9-9: Mitsubishi - Key Financials (Million US$), 2013-2015
Table 9-10: Mitsubishi - Proton Therapy Installations in Japan
Table 9-11: Mitsubishi - Upcoming Proton Therapy Installations in Japan
Table 9-12: Mitsubishi - Strengths and Weaknesses

List of Figures
Figure 4-1: Advantages of Proton Therapy over Conventional Radiation Therapy
Figure 5-1: Components of a Proton Therapy Center
Figure 6-1: Proton Therapy Market (Million US$), 2014-2020
Figure 6-2: Share of Proton Therapy Market in Potential Market (%), 2015
Figure 6-3: Share of Proton Therapy Market in Potential Market (%), 2020
Figure 6-4: Demand of Proton Therapy Centers (2015 & 2020)
Figure 6-5: Shortage of Proton Therapy Centers (2015 & 2020)
Figure 6-6: Share of Vendors by Number of Proton Accelerators Installed (%), 2015
Figure 6-7: Share of Vendors by Number of Proton Accelerators Installed (%), 2020
Figure 6-8: Number of Patients Treated with Proton Therapy for Cancer Type (%), 2013
Figure 7-1: Cancer Incidence ('000), 2012 to 2035
Figure 8-1: Proton Therapy Center by Number of Treatment Rooms (2015 & 2020)

Note: Product cover images may vary from those shown
3 of 4

- Hitachi Medical Corporation (A Subsidiary of Hitachi Ltd.)
- Mitsubishi Electric Corporation
- Sumitomo Heavy Industries, Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: A printed copy of the report will be shipped to you.

  • Quick Help: The report will be shipped to you in CD ROM format.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.